Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside

In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth

“…The drug interacts with tubulin dimers in the G2 phase of the mitotic cell cycle to promote microtubule polymerization; the resulting formation of highly stable microtubules prevents cell division and accounts for the cytotoxic properties of Ptx (Singh et al, 2008). Ptx has excellent therapeutic efficacy against a variety of solid tumors, including breast cancer, ovarian carcinoma, lung cancer, head-and-neck carcinoma, and acute leukemia (de Bree et al, 2006;Singla et al, 2002;Fjällskog et al, 1993). However, Ptx is a hydrophobic molecule that is poorly soluble in water.…”

Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts

“…It is still unknown, however, whether the antitumour effect is mainly related to direct drug tumour penetration, prolonged drug exposure, higher serum drug levels due to absorption, or if IP chemotherapy modifies the immune response against tumour cells in the peritoneal cavity [5]. Patients with microscopic or small volume residual disease seem to be most suitable for this approach, while, in more bulky disease, IP chemotherapy is unlikely to be beneficial because drug penetration is limited [6].…”

Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer

“…chemotherapy is the need for a catheter for drug delivery into the peritoneal cavity. In large clinical studies, catheter complications including obstructions, infections, and bowel perforations accounted for 70% of treatment termination cases (8,9).…”